Neovasc Inc
TSX:NVCN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Neovasc Inc
Common Stock
Neovasc Inc
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neovasc Inc
TSX:NVCN
|
Common Stock
$441.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
21%
|
CAGR 10-Years
20%
|
|
|
Profound Medical Corp
TSX:PRN
|
Common Stock
$323.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
21%
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Common Stock
CA$50.1m
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
10%
|
|
|
MedMira Inc
XTSX:MIR
|
Common Stock
CA$68.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Common Stock
CA$262.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Conavi Medical Corp
XTSX:CNVI
|
Common Stock
$126.8m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
4%
|
|
Neovasc Inc
Glance View
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures and markets products for the cardiovascular marketplace. The firm's products include the Neovasc ReducerTM (Reducer), for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary vasculature delivers an inadequate supply of blood to the heart muscle and the TiaraTM (Tiara), for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. Its wholly owned subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc.
See Also
What is Neovasc Inc's Common Stock?
Common Stock
441.4m
USD
Based on the financial report for Dec 31, 2022, Neovasc Inc's Common Stock amounts to 441.4m USD.
What is Neovasc Inc's Common Stock growth rate?
Common Stock CAGR 10Y
20%
Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Neovasc Inc have been 10% over the past three years , 21% over the past five years , and 20% over the past ten years .
